Abbott launches leadless pacemaker system in India to treat patients with slow heart rates – Health News

Abbott, a global healthcare company, on Thursday announced the release of the AVEIR VR single-chamber ventricular device. leadless pacemaker to treat patients in India with slow heart rate.

According to the company, this pacemaker is approved by the Central Drugs Standard Control Organization (CDSCO) in India. It is also approved by the US Food and Drug Administration (FDA) and marks a significant advance in patient care by providing new features to patients and their physicians.

“People whose heart rate is slower than normal may be given a pacemaker, which will deliver electrical impulses to make the heart beat correctly. While traditional pacemakers require an incision in the chest and a pocket for a generator along with one or more insulated wires, known as cardiac leads, to send electricity to the heart, leadless pacemakers do not require a pocket or wires. Instead, the device is implanted directly into the lower right chamber of the heart (right ventricle) through a minimally invasive procedure using a catheter from the groin. So there is no cut in the chest, no wires, and no pocket in the chest for the generator,” the company said in a statement.

Google Trends: PM JAY portal, Ayushman card criteria among top searches this week

USFDA approves Alembic Pharma’s genetic formula to treat heart failure

Indian Railways is set to introduce an all-in-one ‘super app’ for booking tickets, tracking trains, ordering food and more – details inside

Laying track for bullet trains: Inside India’s 820-crore high-speed rail test track project in Rajasthan

The device has unique mapping capabilities that allow physicians to measure electrical signals in the heart and determine the best placement of the device before final implantation. The predicted battery life compared to currently available leadless pacemakers opens the door to more patients. Additionally, AVEIR is the only wireless pacemaker designed to be removed when the device needs to be replaced or therapy needs to evolve.

“The leadless pacemaker offers a powerful treatment option for people with cardiac arrhythmia or irregular heartbeat. Leadless pacemakers eliminate the known complications associated with traditional pacemakers,” said Dr Balbir Singh, Chairman, Cardiology, Max Superspeciality Hospital. He further added, “Cardiovascular diseases such as heart failure and cardiac arrhythmias constitute a major component of the chronic disease burden in India, and interventional therapies such as pacemakers help improve patient outcomes.”

Data from the global LEADLESS II Investigational Device Exclusion (IDE) study evaluated AVEIR VR in patients with certain abnormal heart rhythms, according to the company. The results showed that the device met its prespecified primary endpoints. The results were presented at the Asia Pacific Heart Rhythm Society (APHRS) Annual Scientific Sessions in November 2021 and simultaneously published in the Journal of the American College of Cardiology: Clinical Electrophysiology.

“The AVEIR VR wireless pacemaker was designed to make implantation and retrieval processes as simple as possible for clinicians and provide improvements over existing options,” said Ajay Singh Chauhan, general manager of Abbott’s heart rhythm management business in India, Southeast Asia. Hong Kong. Taiwan and Korea. “What sets this innovation apart is its impressive battery life and unique mapping and search capabilities. Our goal is to continue to develop the adoption of AVEIR VR to offer more first-of-its-kind products in the future, revolutionizing the treatment of abnormal heart rhythms.”